文献速递类风湿关节炎

阿巴西普治疗类风湿关节炎与癌症风险:全球上市后观察性研究

Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study.
PubMed 文献 · Rheumatology (Oxford) · 2020-01-01

该研究基于WHO VigiBase数据库2007至2017年数据,比较RA患者使用阿巴西普与其他bDMARDs后报告癌症的风险。结果显示阿巴西普整体癌症报告风险未增加(ROR 0.98, 95%CI 0.91,1.05),但黑色素瘤报告风险显著升高(ROR 1.58, 95%CI 1.17,2.08)。

要点

  • 阿巴西普整体癌症报告风险与其他bDMARDs相比无显著增加。
  • 阿巴西普与黑色素瘤报告风险显著升高相关(ROR 1.58)。
  • 其他特定部位癌症未见显著风险升高。

核心结论

  • 与其它bDMARDs相比,RA患者暴露于阿巴西普仅与黑色素瘤报告风险显著增加相关。

研究设计与样本

  • 基于WHO VigiBase数据库2007至2017年个例安全报告的观察性研究,比较RA患者中阿巴西普与其他bDMARDs暴露后报告癌症的失衡分析。

主要发现

  • 阿巴西普组报告15 846例不良反应,其他bDMARDs组报告290 568例不良反应。
  • 整体癌症报告风险无显著增加:ROR 0.98(95%CI 0.91, 1.05)。
  • 黑色素瘤报告风险显著增加:ROR 1.58(95%CI 1.17, 2.08)。
  • 其他特定部位癌症未见显著风险升高。

临床怎么用

  • RA患者使用阿巴西普时应关注黑色素瘤相关皮肤病变的监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: We aimed to investigate whether abatacept used in patients for RA was associated with an increased risk of reporting overall cancer and specific cancers, including breast, lung, lymphoma, melanoma and non-melanoma skin cancer when compared with other biologic DMARDs (bDMARDs). METHODS: We performed an observational study within VigiBase, the World Health Organization's global database of individual case safety reports, from 2007 to 2017 to compare the cases of cancer reported in RA patients exposed to abatacept with those reported in RA patients exposed to other bDMARDs. We conducted disproportionality analyses allowing the estimation of reporting odds ratios (RORs) with 95% CIs of the exposure odds among spontaneous reporting of cancers to the exposure odds among other reported adverse effects. RESULTS: We identified 15 846 adverse effects reported in RA patients who received abatacept and 290 568 adverse effects reported in RA patients treated with other bDMARDs. Compared with other bDMARDs, the use of abatacept was not associated with an increased risk of reporting cancer overall [ROR 0.98 (95% CI 0.91, 1.05)]. Analyses by specific cancer sites showed a significantly increased ROR for melanoma [1.58 (95% CI 1.17, 2.08)], but not for other specific cancer sites. CONCLUSION: Compared with other bDMARDs, exposure to abatacept in RA patients was only significantly associated with an increased risk of reporting melanoma. This increased risk is consistent with the properties of abatacept (CTLA-4 agonist) since it has an opposite action than ipilimumab, an antibody that blocks CTLA-4 and is approved for the treatment of malignant melanoma. TRIAL REGISTRATION: ClinicalTrials.gov (http://clinicaltrials.gov), NCT03980639.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. de Germay S, Bagheri H, Despas F, et al. Abatacept in rheumatoid arthritis and the risk of cancer: a world observational post-marketing study. Rheumatology (Oxford). 2020. PMID: 31880308. doi:10.1093/rheumatology/kez604

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。